A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

This was the stock's second consecutive day of gains.

But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...

Autolus Therapeutics plc delivers a breakthrough CAR-T therapy for B-ALL with strong safety/efficacy. Learn more about AUTL ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

Remdesivir was associated with a significant survival benefit and reduced risk for rehospitalization among inpatients with COVID-19 infection.

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Symptomatic infection with cold sore virus herpes simplex 1 may be implicated in the development of Alzheimer’s disease.

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...